Over the past year, Moderna (MRNA) has been an outlier in the biotech sector. The stock is still up 404% year to date and 515% over the trailing twelve months, trading near $148 per share. Yet that price marks a meaningful retreat from the $176.66 high reached earlier in the year. The pullback has left investors asking whether the rally has run its course—or whether this mRNA leader still has room to deliver long-term returns.
Zoom out to a five-year view, and Moderna remains down more than 60%. The market had worried that fading COVID-19 vaccine demand would cripple a company built around a single blockbuster product. Financial results deteriorated, and there was deep skepticism about whether the mRNA platform could achieve commercial success beyond infectious disease.
Recent clinical and regulatory milestones have begun to change that perception. The pivotal catalyst came from intismeran autogene, a personalized mRNA cancer vaccine. In a Phase 3 trial for melanoma, the candidate was tested in combination with Merck’s Keytruda versus Keytruda alone. The combination therapy showed a significant improvement in recurrence-free survival. Beyond paving a path toward approval, the result marked the first time an mRNA cancer vaccine delivered such strong Phase 3 data. That revalued Moderna’s entire oncology pipeline—including programs in lung, bladder, and kidney cancers—and sent the stock up more than 100% in a single day.
Outside oncology, the flu vaccine mFLUSIVA also won approval this year. Phase 3 data showed it outperformed some marketed influenza vaccines. With the global flu vaccine market estimated at roughly $8.9 billion last year, mFLUSIVA could capture a meaningful share. Analysts project intismeran autogene could reach $5.6 billion in peak sales, with Moderna and Merck splitting revenue on a 50/50 basis.
Bears argue that Moderna’s current market capitalization of $59.4 billion and a price-to-sales ratio of 27.5 look expensive for a company generating limited revenue and still posting losses. Even with new vaccines rolling out, whether the business can justify such a multiple remains an open question.
Bulls counter that Moderna’s core asset is not any single product but a validated mRNA platform. That platform has already produced a COVID-19 vaccine and a flu vaccine, and has now delivered breakthrough clinical data in cancer. Over the next five years, multiple pipeline candidates could generate further clinical progress. Even if some programs fail, key wins could keep driving the stock higher. As COVID-19 revenue fades into a smaller role, new products are expected to provide steadier top-line growth, shifting the company’s identity from pandemic play to broad-based mRNA drugmaker.
In the short term, a 27.5 price-to-sales multiple for an unprofitable biotech is undeniably elevated, and some pullback after a triple-digit single-day surge is hardly surprising. But on a five-year view, Moderna holds a deep pipeline across respiratory viruses, rare diseases, and oncology, with dense clinical catalysts ahead. The Phase 3 validation of mRNA technology in cancer vaccines dramatically expands the commercial imagination around the platform.
The answer is not complicated: Moderna’s valuation is not cheap, but the market is willing to pay a premium for the optionality embedded in a platform drugmaker. For investors who can tolerate volatility, the current dip may be less a signal to exit than a chance to reassess the entry point.
